Affiliation:
1. Faculty of Applied Health Sciences, Medical Laboratory Science, Hashemite University, Zarqa, Jordan
2. Faculty of
Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan
3. Faculty of Medicine, Ophthalmology,
Jordan University of Science and Technology, Jordan
Abstract
Abstract:
Restoring everyday civil life from the devastating pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) can be only by the development of an efficient vaccine. As of
April 12, 2022, 497,960,492 confirmed cases of COVID-19 were reported, including 6,181,850 lives
having been lost worldwide and completely paralyzing the d global economy. Detection of a novel
coronavirus SARS-CoV-2 in Wuhan, in December 2019, and the genetic sequence of SARS-CoV-2
that was published on January 11, 2020, leads to a global race, to prepare for a preventive vaccine. No
single institution can develop a vaccine individually because there are many stages for developing and
producing a successful vaccine. Since this virus threatens the health, the economy, and society the
demand for a fast-track vaccine is understandable. This article tries to give an overview of vaccine
'candidates' development and clinical trials, and it mentions some challenges of using these vaccines
for managing SARS‐CoV‐2.
Publisher
Bentham Science Publishers Ltd.
Subject
Microbiology (medical),Pharmacology,Molecular Medicine,General Medicine